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Abstract
Background: With the proliferation of rare disease registries, there is a need for registries to undergo an
assessment of their quality against agreed standards to ensure their long-term sustainability and acceptability.This
study was performed to evaluate the I-DSD and I-CAH Registries and identify their strengths and weaknesses.
Methods: The design and operational aspects of the registries were evaluated against published quality indicators.
Additional criteria included the level of activity, international acceptability of the registries and their use for
research.
Results: The design of the I-DSD and I-CAH Registries provides them with the ability to perform multiple studies
and meet the standards for data elements, data sources and eligibility criteria. The registries follow the standards for
data security, governance, ethical and legal issues, sustainability and communication of activities. The data have a
high degree of validity, consistency and accuracy and the completeness is maximal for specific conditions such as
androgen insensitivity syndrome and congenital adrenal hyperplasia. In terms of research output, the external
validity is strong but the wide variety of cases needs further review. The internal validity of data was condition
specific and highest for conditions such as congenital adrenal hyperplasia. The shift of the registry from a European
registry to an international registry and the creation of a discrete but linked CAH registry increased the number of
users and stakeholders as well as the international acceptability of both registries.
Conclusions: The I-DSD and I-CAH registries comply with the standards set by expert organisations. Recent
modifications in their operation have allowed the registries to increase their user acceptability.
Keywords: Congenital adrenal hyperplasia, Data quality, Disorders of sex development, Research quality, Validity
Background
By enabling surveillance, audit and research through a
virtual environment, registries have the potential to
improve the care of people with rare conditions and
diseases. These registries may be particularly useful for
heterogeneous groups of rare conditions such as disor-
ders of sex development (DSD) where the perceived
stigma of the condition, the gaps in knowledge about
aetiology and long-term outcome and the lack of expert
and evidence-based multidisciplinary care result in sub-
stantial variation in patient care and disaffection [1]. In
such situations, important lessons can only be learnt
through the pooling of data within a common, se-
cure platform and through effective interaction be-
tween researchers, health care professionals and the
affected community. In the field of DSD, the impetus
for this need for collaboration was set in motion
following the consensus meeting a decade ago and
has been sustained through further initiatives such
as EuroDSD, I-DSD and DSDnet [2]. The registry in-
frastructure that has developed from these efforts
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initially involved a handful of centres in Europe but
currently involves clinical users from all five conti-
nents. These health care professionals provide care
for a range of conditions affecting sex development
as well as congenital adrenal hyperplasia and the
two registries, I-DSD and I-CAH, that have devel-
oped have now started to demonstrate their ability
to perform several functions including research, pa-
tient management, patient accessible records and for
clinical and expert networking.
As the I-DSD and I-CAH registries mature, the
need for ensuring the quality and value of these regis-
tries becomes more important especially if there is a
need to sustain them over the longer term. Until re-
cently, there was little guidance around the criteria
that could be assessed to explore the quality of a rare
disease registry [3]. This study has been performed to
describe the most important features of the I-DSD
and I-CAH registries that allow them to be compared
against quality benchmarks. In addition, the study
also explores additional quality criteria that could be
considered in the future.
Methods
The evaluation of the quality of I-DSD and I-CAH
Registries considered two domains; research quality and
evidence quality [3]. Additional criteria were considered re-
lated to the level of activity, the international acceptability
and the networking function of these Registries (Fig. 1).
Research quality
Research quality was evaluated by assessing the design of
the registries, their operational protocols and the quality
of data. The design of the I-DSD and I-CAH registries
was assessed according to criteria set by the Agency for
Healthcare Research and Quality to protect against bias
[3] (Table 1). The operational aspects of the Registry were
compared to standards defined by the EPIRARE survey on
a representative sample of 220 European rare disease
registries [4]. The set of variables found to characterize
high-quality RDRs according to this survey focused on
ethical and legal issues, governance, communication of
activities and results, established procedures to regulate
access to data and security and established plans to ensure
long-term sustainability (Table 2).
Fig. 1 The assessment model of the I-DSD and I-CAH Registries
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The quality of data was assessed according to six pri-
mary factors set by the International Data Management
Association and as summarized in Table 3 [5]. These
data quality factors were assessed by analysing the data
of the registry against itself, and by verification of all the
case record except for timeliness and accuracy for which
a subset of cases was used. The accuracy was difficult to
assess because we needed to compare data in the regis-
try with original data from centres which was not
possible because of ethical and legal rules that protect
data and prevent from identification of cases in the
registry. The exercise was performed only for 23 PAIS
cases where original data provided by centres were avail-
able in nine variables including phenotype evaluation by
the EMS because of an ongoing study.
In terms of completeness, the core data were assessed
separately as they represent the minimum mandatory
requirement for cases to be eligible for entry in the
registries. Further assessment of completeness of data
was performed by diagnostic categories of conditions.
An assessment of completeness of optional data fields
also allowed a deeper insight into willingness of partici-
pating centres to provide complete data. The timeliness
of data entry was evaluated in cases where the year at
first presentation was 2008 or later as that was the year
of the creation of the Registry. Only cases added by
Table 1 Data quality indicators of Registry design that affect
the quality of Research derived from the Registry according to
the Agency for Healthcare Research and Quality
Parameter Criteria of good Quality practice for
Research
Purpose of the Registry -Research questions clearly defined
-Meet the needs of key stakeholders
-The Registry should be an appropriate/
the best means to achieve the purpose
Study Design Choice of study design which is more
efficient for addressing the research
questions: Cohort, Case-control or
case-cohort.
Data elements Relevance to the objectives of the registry
Acceptability to subjects and researchersa
Validityb
Reliabilityc
Use of standardized data collection form
CDISC, CDASH, BRIDG when possible
Use of disease coding system ICD coding
system, MIM, ORPHA codes
Data sources (good quality
means the use of the
appropriate data sources
to collect relevant data)
Clinician:accurate and specific clinical data
Patient:data on health-related quality of life,
utilities (patient preferences), behavioral
data, family history.
Electronic Health Record: information on
routine medical care and practice,
comprehensive view of patient medical
and clinical history.
Linkage with other sources:data difficult
to obtain, subject to recall bias, not
collected because of loss to followup, or
likely inaccurate by self-report.
Population definition - Patient selection: inclusion and exclusion
criteriarelevant to the purpose
- Patient sampling: consider
representativeness in terms of patients
and sites
Registry size and duration Calculation of target sample size and
definition of the duration of enrollment
and follow-up should consider the aims
of the registry, the desired precision of
information sought, and the hypotheses
to be tested.
CDISC Clinical Data Interchange Standards Consortium
CDASH Clinical Data Acquisition Standards Harmonization
BRIDG Biomedical Research Integrated Domain Group
areasonably feasible to collect, minimal response burden
bdoes each data element truthfully measure what it is supposed to?
ccan the instrument yield replicate metrics or estimates?
Table 2 Criteria of evaluation of quality of operational aspects [4]
Quality indicators Profile of High Quality Rare Disease Registries
Ethical and Legal
issues
-Protocols are approved by ethics committee.
-Transparency of activities, oversight, data
ownership and data delivery, and conflict
of interest
-Patient confidentiality, informed consent.
Access to data and
security
-Data are made available anonymously to
public institutions, public authorities, patient
associations and private institutions/citizens,
centres of expertise within the country and
worldwide
-Security is ensured by hosting data in a
dedicated server and by an intrusion
detection system. Having an approval by




Communication to data providers, public health
policy makers and patient associations through
websites, newsletters, institutional bulletins,
scientific meetings and journals resulting in
peer review by scientific journals and scientific
meetings
Governance A main governing board composed by internal
and external experts has a good oversight and
governance mechanisms dealing with financial,
administrative, ethical and legal issues, research
objectives, database content, data access and
use, communication and coordination of all
stakeholders.




-Case definition for the Rare Disease of interest
-Standardized inclusion/exclusion
-Data entered/sent (online/electronically) by
data providers
-Data periodically updated
-Application of methods to avoid data entry
mistakes
-Use of quality indicators
-Application of methods to check for reliability,
agreement and internal validity
-Periodic performance of quality tests/surveys
-Application of methods to avoid duplication of
registered cases
-Availability of instructions for use of the registry
-Provision of training or of a training kit for new
users
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centres enrolled between 2008 and 2009 were included
to avoid any bias introduced by the later enrolment of
centres. The assessment of accuracy was performed by
verifying a subset of data against original source data.
External validity of data
The external validity of the registries was assessed by an
evaluation of three broad criteria. Firstly, the representa-
tiveness of the actual population in the registries as
assessed by both quantitative and semi-quantitative
methods. The quantitative assessment compared the
actual population to the target population in terms of
absolute numbers. The studied actual population in the
I-DSD Registry was 46 XY DSD cases assigned boys
excluding CAH patients, uploaded by one centre, Glas-
gow, between 2010 and 2015 and shared internationally,
because original source data were easily accessible in that
centre for the same period (Fig. 2) The semi-quantitative
assessment concentrated on the age distribution, the
geographic distribution and the distribution of three
conditions in the registries - CAH, AIS (Androgen
Insensitivity Syndrome) and disorders of Müllerian
development and was performed at two time points
(2010 and 2016). This distribution was then compared
with estimated incidence of these disorders according to
published epidemiological data. The second criterion for
assessing external validity was the completeness of infor-
mation in the actual population and lastly, the third criter-
ion that was assessed was case-attrition which was
evaluated by calculating the number of patients or centres
that had withdrawn from participation in the registries.
Internal validity of data
The internal validity of the registries was assessed, firstly,
by an evaluation of the extent of selection bias in the I-
DSD registry evaluated by a study of the representative-
ness of cases described previously in Fig.1. In addition, in-
ternal validity was assessed by examining the information
bias in the I-DSD Registry for cases of partial androgen
insensitivity syndrome (PAIS) by assessing the discordance
between a specific dataset relating to the external mascu-
linisation score (EMS) at first presentation in the registry
and EMS at first presentation in source data obtained by a
separate template filled by clinicians for the same cases
when participating in a previous study using the registry
[6]. Lastly, internal validity was also assessed by studying
the extent of misclassification of cases of XY DSD
that had been classified as PAIS despite the absence
of mutations in the androgen receptor gene.
Level of activity & information quality
This was evaluated by the calculation of the rate of enroll-
ment of centres in the Registry as network and clinical
users, the progress of the percentage of centres adding
new cases and the overall rate of addition of cases per
year. The quality of research output was assessed by de-
scribing the number of completed studies and active stud-
ies using the registry and the number of users who were
Table 3 The 6 Data Quality Dimensions defined by DAMA UK Working Group for data quality assessment
Data quality dimensions Definition Measure in the Registry
Completeness The proportion of stored data against the potential
of “100% complete”.
- Optional variables in Core data
-All variables by disorders in all data
-Optional variables by centresin all data, separately
in the I-DSD and I-CAH Registries
-Optional data in CAH longitudinal module
Uniqueness No thing will be recorded more than once
based upon how that thing is identified.
Uniqueness is the inverse of an assessment of
the level of duplication.
Percentage of duplicated cases by measuring data item
against itself. A case is presumed duplicated when there
is 100% similarity in core data and more than 90%
similarity in non-core data between duplicates.
Timeliness The degree to which data represent reality from the
required point in time or how current or up to date
the data are at the time of release.
Timeframe between the age at first presentation and the
upload date in the Registry
Validity Data are valid if it conforms to the syntax (format, type, range)
of data definition.
The percentage of data that are not conform to the
syntax in the longitudinal module in the ICAH Registry
(Blood pressure)
Accuracy The degree to which data correctly describes the “real world”
object or event being described.
The accuracy of data in PAISa cases in the Registry was
verified against original data available in templates
completed by centres
Consistency The absence of difference, when comparing two or more
representations of a thing against a definition.
Consistency between the number of adverse events
episodesb and sick days in the longitudinal module
of the I-CAH Registry
(When the data provider enter a number of adverse events, a table with a number of rows corresponding to the number of adverse event episodes is displayed
and in each row we need to complete the number of sick days in each adverse event episode. The total number of sick days is automatically calculated.
Obviously, the number of adverse events should not exceed the number of sick days, otherwise, there is an inconsistency between the two variables)
a PAIS Partial androgen insensitivity syndrome
b Adverse events: are the number of separate episodes of illness requiring extra dose of steroid
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using the registries for research. The types of these studies
were also evaluated.
The international acceptability of the registries
This was assessed by calculating the rate of enrollment of
non-European centres and the rate of addition of cases by
these centres as well as the participation of non-European
users in research using the Registry. The registries allow
the clinical user to share their data according to four
levels: international, European, national and local level
only and the change in the level of sharing was assessed as
a marker of internationalization of the registries.
The professional networking function of the registries
This was evaluated by the calculation of the rate of en-
rollment of centres for networking purposes. The input
of the project management group of the I-DSD Registry
and I-CAH in other international networks (DSDnet,
DSDlife, CAH-UK) and position statements was used as
a marker of the networking function of the registries.
Statistical analysis
Continuous variables were described as median and
ranges and intergroup comparison for these variables
was performed by Mann Whitney U tests. Chi-square
test was used for categorical variables. P < .05 was con-
sidered to be statistically significant and all analyses were
performed using SPSS for Windows software program,
Version 22 (SPSS. Chicago, IL, USA).
Results
Measures for ensuring research quality
Design
The registries were developed to allow multiple studies
using an observational study design based on a cohort of
patients with DSD. The data elements could facilitate
epidemiologic, genetic and clinical research. Only simple
data that are routinely collected as part of clinical care
are required allowing the participation of different cen-
tres. The original data elements were selected by a con-
sensus around a case report form based on the revised
DSD nomenclature [7]. Only clinicians approved by the
Project Management Group and who are members of
recognized professional societies can enter data in the
Registry. The eligibility criteria for cases are broad as
any adult or child with a condition associated with a
DSD at a centre with an approved clinician can be in-
cluded after obtaining consent. There are no restrictions
regarding the number or characteristics of uploaded
cases and this is left to self-selection by the clinician. As
the registries were developed to allow multiple studies,
the calculation of target sample size and follow up
period is only undertaken when a new study is planned.
The comparison groups are usually chosen from cases in
the Registry. Centres are invited to participate in the
new study, and they enter the required number of cases
that fit the inclusion criteria for that study.
Operational protocols
The operational protocols for the registries have been
approved by the UK NHS Information Governance
Body, the UK Research Ethics Committee and the Ethics
Committee of the former EuroDSD project funded by an
EUFP7 grant. Ethical rules take into account the hetero-
geneity of legal structures of participant countries in
terms of patient confidentiality, consent and regulations
for biomaterial. The registries ensure data security by
hosting data on a dedicated server and by using an in-
trusion detection system. Only clinical users and project
management team can access the data that they have
Fig. 2 Description of the populations in the I-DSD Registry
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entered. Searching for data at centres other than the
user’s centre is only possible via the project management
team. In addition, a new option has been created to en-
able patients to access a portion of their record. The
registries communicate their activities to a range of
stakeholders including registry users, patients and their
associations through regular presentations in national
and international scientific meetings, via a website [8]
and through 6-monthly newsletters. For governance, the
Steering Committee is composed of clinical and non-
clinical experts who provide the oversight and advise the
project management group which coordinates the day-
to-day activities including quality assurance of the regis-
tries. The registries were initially developed through
funding received from the European Society for Paediat-
ric Endocrinology, EUFP7 grant and the UK Medical
Research Council. In the future, the sustainability of the
registries will be dependent on project based funding
and this has been demonstrated by its role in supporting
new studies such as CAH-UK and PRO-CAH and its
close links to the pharmaceutical industry.
Data quality
In order to ensure high quality data, the registries have
implemented quality assurance procedures such as auto-
mated data cleaning which is performed by automated
validation of data entry within a pre-defined range for
some data fields such as weight, height, blood pressure,
prevention of entry of alphabetic data in numeric fields
(date, age), automated calculation of external
masculinization score and deactivation of unnecessary
data fields so that erroneous entries cannot occur. The
data entry option ‘Yes’ ‘No’ ‘unknown’ and the option
‘Other’ in drop down lists allows the distinction between
undocumented data and missing data and limited free text
is included to add information not covered by the case re-
port form. Description of some physical features such as
the genitalia has been standardized by the use of Prader
classification and EMS which are accompanied by visual
cues as well as textual description. To avoid record dupli-
cation, each registered case is assigned a unique identifier
associated with the local records at the data entry site. A
comprehensive review of the data entered is generally only
performed when the data are used by the biomedical com-
munity for research purposes. Instructions for the use
of the Registry are available at the University of Glas-
gow website [9].
In terms of data completness, the results of assessment
of this quality indicator are available on Table 4. The
median extent of completeness of optional data per
case in the registries for DSD and CAH was 66%
(4%-93%) and 52% (2%-87%) (p = 0.11). Of the 31
centres adding CAH cases, 15 (48%) had not only
completed the cross-sectional module but were also
completing the longitudinal module in 173 cases
(30%). Of these 15 centres, 2 centres with an average
of 40 CAH and 105 DSD cases each were consistently
achieving a level of data completion of greater than
80%. Evidence of duplication using 68 variables was
checked in 2155 cases and the number of duplicated
cases was identified as 44 (2%). The timeliness of data
entry was evaluated in 186 cases from 7 centres and
the median time between age at first presentation and
date of upload was 1 year (0-7). The validity of data
entry was 100% when assessed for the blood pressure,
the height and the weight in 314, 513 and 540 fields
of 657 CAH visits respectively where data were avail-
able. Accuracy was checked in 23 cases of PAIS using
9 variables and an inaccuracy was found in 11 of the
207 fields (5%). In addition, inconsistency between
the number of sick days and adverse events episodes
was found in 28 of 165 visits (0.17%) where data were
available.
External validity
The quantitative assessment of representativeness shows
that 69/122 cases (56.5% of the patients enrolled in the
centre) are entered in the Registry and 53/122 cases
(43.5%) are shared internationally. The median year of
birth of 2155 cases entered in the registries was 2000
(1927-2016) with 1073 (50%) over 16 yrs. The median
age at first presentation was 1-3 months (<1 month-
63 years) with 149 from 1702 where information were
available (8.7%) presenting over the age of 16 years. In
2009, user involvement was limited to 11 centres from 8
countries in Europe only. However, the percentage of
cases added per year by non-European centres has in-
creased significantly. Currently, cases have been entered
from 55 centres from 26 countries from 5 continents.
The majority of cases (1620;75%) are from 38 centres in
15 European countries and the majority of these are
from the United Kingdom (491; 23%), Germany (275;
13%), Netherlands (264; 12%) and Italy (204; 9%). Of the
535 (25%) cases entered from 17 centres in 11 countries
outside Europe, 268 (13%) are from Turkey and 132
(6%) from Egypt. There has been a shift in the propor-
tion of cases with CAH that have been entered in the
registries. The percentage of CAH cases added per year
has increased by more than 6 fold (Fig. 3) and the per-
centage of centres adding these cases has followed the
same pattern. In terms of distribution of conditions, the
representativeness of the registry has increased. The pro-
portion of cases of CAH compared to AIS (Androgen
Insensitivity Syndrome) expressed by the CAH:AIS ratio
has changed from 0.5 in February 2010 to 1.2 in May
2016 in the I-DSD Registry. This is approaching the
estimated ratio in the population calculated by the esti-
mated incidence of 1 in 15,000 for CAH [10] and of
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Table 4 Completeness of data in the I-DSD and I-CAH Registries in core data, according to disorders and in optional data by centres






Optional Core data All cases in








All data Data in each disorder in
all cases in the
I-DSD and I-CAH Registries
n1 = 2155
(CAH Longitudinal module excluded)
n = 61 -Other (n1 = 144) -Disorder of gonadal
development (n1 = 418)
Disorder of androgen
synthesis (n1 = 247)




Syndrome (n1 = 15)
-Cloacal anomaly (n1 = 4)
-CAH (n1 = 604)
-Disorder of androgen




development (n1 = 17)
Optional data Data by centre in the
I-DSD Registry
n1 = 1551
n = 55 n3 = 17
n2 = 2 (1-224)
n3 = 9
n2 = 26 (6-91)
n3 = 20
n2 = 18 (1-122)
Optional data Data by centre in the
I-CAH Registry
n1 = 604
n = 55 n3 = 14
n2 = 16 (1-54)
n3 = 10
n2 = 15 (5-59)
n3 = 7
n2 = 2 (1–26)
Optional data Longitudinal module in
the I-CAH Registry
n1 = 173





n2 = 26 (4-72)
-Total Number of variables in the non longitudinal module; which is a common module between the two Registries; is 65 with 4 identifiers so, we assessed 61
variables with 6 variables which are mandatory to complete and 55 which are optional
-The core data mean the data that need completion in order to consider a case for a study. It contains the 4 identifiers, 3 mandatory variables (year of birth,
Original Sex Assigned, Karyotype, and disorder type) and 2 optional variables (age at presentation and actual diagnosis)
-Total number of variables in the longitudinal module in the I-CAH Registry is 47
n number of variables
n1 number of cases
n2 median number of cases per centre (range)
n3 number of centres
Fig. 3 The rate of addition of new cases per year in the I-DSD and I-CAH Registries. n: Number of new cases added per year. N: Total number of
cases in the Registry at the time of analysis
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between 1:40,800 and 1:99,000 for AIS [11] with a
CAH:AIS ratio between 2.5 and 6. However, other con-
ditions that are associated with DSD such as disorders of
Müllerian development (MRKH: Mayer-Rokitansky-
Küster-Hauser syndrome) which have an incidence of
MRKH in the population of 1 in 4,500 are underrepre-
sented [12]. Thus the condition is 4.5 fold more frequent
than AIS but the MRKH:AIS ratio in the registry was
0.02 and 0.03 respectively in Februray 2010 and in May
2016 . Concerning case-attrition, there was no with-
drawal within participating centres in the registries and
there have been no requests for deleting the records of
any patients from any centres.
Internal validity
It is likely that self-selection by clinicians of cases to up-
load into the registries and the consent process, itself,
introduces a selection bias in the registries. This has not
been explored systematically across all users. An assess-
ment of information bias revealed that of 23 cases
assessed, in 5 cases (22%), the EMS at first presentation
was different between the data in the I-DSD registry and
the source data. There were 249 cases in the I-DSD
Registry with a PAIS-like phenotype. Of these, 211 (85%)
were categorised as Disorder of Androgen action “PAIS”,
18 (7%) as Disorder of Androgen action “Other”and 20
(8%) as non-specific disorder of under masculinization,
thus showing a measurable level of misclassification.
Level of activity and information quality
The rate of enrollment of centres has more than doubled
between 2009 and 2015 with two clear peaks (Fig. 4).
The first surge coincided with the move from EuroDSD
Registry to I-DSD Registry. The second surge coincided
with the creation of a dedicated I-CAH Registry. The rate
of addition of cases has followed the same pattern (Fig. 3).
Completed studies using the Registry have led to six
publications and 25 presentations at international sci-
entific meetings. Currently, there are 12 additional ac-
tive studies and 9 submitted for approval. Of the 279
Registry users, 65 (23%) have used the Registry for re-
search, with a median number of studies per user of
2 [1, 11]. Of the 65, 18 (30%) of users are from out-
side Europe. The type of studies range from basic
studies aimed at characterizing the DSD population
[13] to those exploring trends in practice [14, 15] and
novel associations [16] as well as frequency of adverse
events [6, 17] The research output of these studies
contributes to better outcome of patients. The study
investigating novel associations has demonstrated that
the rate of associated conditions is 10 times the birth
prevalence of congenital anomalies [16] highlighting
the need for input from multiple specialists with a
multidisciplinary model of care. The poorer long term
outcome of cases with confirmed PAIS compared to
cases without Androgen Receptor mutation [6] em-
phasizes the necessity of AR analysis early in order to
personalize care. The study investigating adverse events
will contribute to better management of CAH patients
with better definition of optimal doses of replacement
therapy [17]. Other studies included the assessment of the
practice of the users of the registries [18].
International acceptability of the registries for research &
networking
The proportion of non-European users enrolling annu-
ally has doubled from only 25% in 2010 to 50% of new
users in 2015 (Fig. 5). In addition to uploading details of
cases, there has also been an increase in the rate of
enrollment of centres for networking purposes (Fig. 4).
Of the 279 users, 188 (67%) are from Europe and of
these 188 registered users, 47 (25%) are involved in
Fig. 4 The rate of enrolment of new centres per year in the I-DSD and I-CAH Registries. n: Number of new centres enrolled per year
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performing research. Of the 91 registered users from
outside Europe, 18 (20%) are using the registries for per-
forming research. Furthermore, with the involvement of
more centres beyond Europe, the scope of data sharing
has also increased so that more data are shared inter-
nationally rather than just simply within Europe (Fig. 6).
This observation also applies to centres within Europe.
Currently, 47 (86%) centres are sharing data internation-
ally and only 2 (4%) are sharing data locally only. The
networking function of the registries has allowed the
registry users to play leading roles in initiatives such as
EuroDSD [19], DSDlife [20] EU COST Action DSDnet
[21] the recent global DSD update [22] the response to
the EU Commissioner [23], a survey of DSD centres
[18], a survey of clinical psychology support at DSD
centres, and a biennial international meeting for DSD.
The patient engagement in the registry demonstrates the
acceptability in the patient community. Patient support
groups are actively involved in the steering committee
and participate in all decisions concerning the
Fig. 5 The rate of enrolment of European and non-European users in the I-DSD and I-CAH Registries. n: Number of new users. %: Percentage of
new non European users
Fig. 6 The evolution of the level of data sharing in the I-DSD and I-CAH Registries. n: Number of new cases per year shared at a certain level
(international, national….). N: Total Number of cases in the Registry shared at that level at the time of analysis
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governance of the registry. As part of a COST Action,
DSDnet, a workshop for patients and parents was orga-
nized in Bologna in October 2016 to identify the needs
of patients from the registry, their preferences in terms
of consent and access to data and research priorities. A
web-based module within the registry has also been created
enabling patients to view their data and to stay informed
about active studies and express their preferences in
healthcare and research.
Discussion
According to Orphanet, there are over 650 registries for
rare conditions [24]. With the proliferation of registries
for rare conditions, it is imperative that these valuable re-
sources undergo a quality assurance check so that they
can be sustained for longer. The current study represents
a comprehensive assessment of the quality of such a regis-
try against standards that were recently suggested [3, 4].
Desirable qualities of disease registries include a com-
prehensive and collaborative approach to patient data
collection that can ultimately address the requirements
of patients, researchers and regulatory agencies [3, 25].
The design of the Registries meet the standards set in
order to optimize their output in terms of the clarity of
the purposes which consider all stakeholders perspec-
tives, the study design and the broad inclusion criteria
that allow multiple studies and generalisability of results,
the entry of data by experienced specialized clinicians
which contributes to data quality. The inclusion of
patient reported data in the near future along with the
use of a coding system will enhance further the quality
of the design.
In terms of operational aspects of registries, high qual-
ity registries are prioritizing ethical and legal standards
and are expected to provide access to data on a platform
that ensures data security and patient confidentiality.
Registries should ensure that they employ communica-
tion strategies that allow the dissemination of research
activities and their results, thus promoting wider in-
volvement of the stakeholders and ensuring adaptability
and sustainability. Of the 272 registries surveyed by
EPIRARE, 57% were not patient-based, 48% did not have
a clear strategy for long-term sustainability, 34% did not
have a clear management group, 30% did not share data,
21% were established without any clear funding and only
18% were truly international [26]. The I-DSD and I-
CAH registries have met these benchmarks through a
strong governance model which reflects both expertise
and representation of several stakeholders including pa-
tients at all levels of their development, management
and maintenance. The Registry has considerable accept-
ability in the patient community as demonstrated by a
survey of patients where more than 90% of the respon-
dents wanted to use the registry to access information
regarding diagnosis, surgery, investigations, genetics and
medication [27].
Participation in research and ensuring a regular re-
search output is vital for a thriving registry. Not only
have the I-DSD and I-CAH registries been used for per-
forming research but they have also shown their ability
to facilitate the development of a professional network.
By using the registries to perform surveys of specialist
health care provision [18] and by supporting a biennial
international conference, the registries have attempted
to become an integral tool for professional clinical
networking as well as research collaboration.
In terms of data quality, the two registries that we
studied exhibit, both, strengths and opportunities for
improvement. As expected, the completeness of the data
was higher for conditions such as disorders of androgen
action and congenital adrenal hyperplasia and this may
reflect the current focus of research [6, 14–17] Whilst, it
is possible that this may introduce a level of selection
bias and limit future studies to these specific conditions,
it was interesting to note that centres that achieved a
high level of completeness of data for these conditions
also showed a high level of data completion for a wider
range of conditions included within the registries. Thus,
it seems that participation of centres in studies is related
to greater and wider involvement that extends to other
conditions within the registry that are beyond the areas
of current focus. These active centres can act as the
exemplars for the future as they adhere to one of the
recommended quality criteria for centres of expertise for
rare conditions that stipulates that such centres should
participate in registries for rare conditions. Whilst it is
possible that many more centres collect these data in
local registries [18] for rare conditions, full participation
in international registries has to be considered the gold
standard for centres of expertise that are truly interested
in driving the extent of research and quality of care [25].
Not only does a high level of participation increase the
potential for meaningful research but it also increases
the external validity of registries themselves. Although
the external validity of the I-DSD and I-CAH registries
was considered to be high when considering the hetero-
geneity of the population in terms of the distribution of
age, geography and ethnicities as well as the representa-
tiveness of centres with different practices, the selection
bias in cases included in the registries will need further
attention. The high level of external validity of these
registries is also illustrated by the relative ease with
which the original I-DSD registry was used as a platform
to develop the I-CAH registry.
The estimation of duplicated cases in the current quality
assurance exercise was assessed to be low and similar to
that reported by other registries that checked duplicates
against the original source data [28]. Although the I-DSD
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and I-CAH Registries are not truly epidemiological regis-
tries, they have been successfully used to show temporal
trends in practice [14, 15] and the prevalence of associated
conditions [16]. However, the assessment of timeliness of
data entry showed that a period of one year is possible
and if this period of data entry was possible across all par-
ticipating centres, then the registries would reach the level
of timeliness that is commonly required by other registries
such as the ones in the field of childhood cancer that
regularly report annual incidence [29]. Assessing the
accuracy of data in an international registry can be chal-
lenging due to restrictions imposed by geography as well
as rules on confidentiality. To maximise the accuracy of
the data as well as minimise the burden on the reporting
clinician, the registries have limited the mandatory set of
required data fields entry to a minimum. There is also a
large concern on the accuracy of phenotype description
due to variability of report between users. Measures are
also undertaken in order to reduce this variability; a data
dictionary is included in the assessment module as well as
images in order to make the descriptions more uniform
between data providers. Charts for penile and Clitoral
length reference range are also included. The EMS is auto-
matically calculated after data entry in order to minimize
the risk of error. In addition, the registries have relied on
checking accuracy by participation in specific studies and
this exercise showed that the current rate of inaccuracy of
5% is comparable to that reported for other long-standing
established registries [28, 30, 31]. This rate of inaccuracy
could be considered as low and acceptable if it is random
rather than systematic. However, an assessment of this will
require the registries to explore other strategies to check
inaccuracy such as random sampling of cases. It is also
possible that a greater level of scrutiny of their personal
data by the patients themselves may also lead to an im-
provement in data quality. The internal validity of the
registries was considered to be strong when considering
the structure of data elements in the I-CAH Registry that
collected all factors that contribute to the outcome as well
as potential confounders. However, it is possible that the
information bias and misclassification can be reduced
further by the use of data dictionary and training in data
collection procedures.
Historically, the lack of a suitable ontology for rare
conditions within commonly-used classifications of dis-
eases, such as ICD, was one of the key drivers for the de-
velopment of registries for rare conditions. In the field
of DSD, this need was particularly apparent following
the creation of the new nomenclature in 2005 [7].
Although the incorporation of this nomenclature in the
I-DSD and I-CAH registries has allowed rapid accept-
ance of the registries by its core clinical users, the
unique classification may, on the other hand, limits its
interoperability with other registries for rare conditions.
Around 25% of cases of DSD may have an anomaly in a
system other than sex development [16]. An ability for
the registries to map to Orphanet codes [32] as well as
future versions of ICD that include more rare conditions
[33] will need further exploration. With the increasing
number of registries for rare conditions there is an in-
creased likelihood that the same patient may be included
in more than one registry and there is also the need to
consider cross-talk between registries. In addition to a
global unique identifier, it is likely that the inclusion of
common data elements in the I-DSD and I-CAH regis-
tries as suggested by EUCERD, would allow greater
interoperability and facilitate compliance with the guid-
ing principles for scientific data management [34, 35].
More recently, the I-DSD and I-CAH registries have
started to offer patients access to their data through a
web-based portal. This is a facet to these registries which
will be developed further over the coming years so that
the registries can collect patient reported outcome data.
Conclusion
An assessment of the quality of the I-DSD and I-CAH
registries against recent standards set for registries for
rare conditions has demonstrated a high level of compli-
ance with these standards. The assessment has also re-
vealed some deficiencies which will be addressed as the
project develops further. Registries for rare conditions
should routinely undergo a quality assessment exercise.
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